

Chapter 143

Genetic Immunodeficiency Diseases

Ramsay L. Fuleihan & Amy S. Paller

REFERENCES

1. Cunningham-Rundles C, Ponda PP: Molecular defects in T- and B-cell primary immunodeficiency diseases. *Nat Rev Immunol* 5:880, 2005
2. Conley ME et al: Mutations in btk in patients with presumed X-linked agammaglobulinemia. *Am J Hum Genet* 62:1034, 1998
3. Conley ME, Dobbs AK, Farmer DM: Primary B cell immunodeficiencies: Comparisons and contrasts. *Annu Rev Immunol* 27:199, 2009
4. Conley ME et al: Genetic analysis of patients with defects in early B-cell development. *Immunol Rev* 203:216, 2005
5. Conley ME, Howard V: Clinical findings leading to the diagnosis of X-linked gammaglobulinemia. *J Pediatr* 141:566, 2002
6. Lederman HM, Winkelstein JA: X-linked agammaglobulinemia: An analysis of 96 patients. *Medicine (Baltimore)* 64:145, 1985
7. Castigli E, Geha RS: Molecular basis of common variable immunodeficiency. *J Allergy Clin Immunol* 117:740, quiz 747, 2006
8. Chapel H, Cunningham-Rundles C: Update in understanding common variable immunodeficiency disorders (CVIDs) and the management of patients with these conditions. *Br J Haematol* 145:709, 2009
9. Cunningham-Rundles C, Bodian C: Common variable immunodeficiency: Clinical and immunological features of 248 patients. *Clin Immunol* 92:34, 1999
10. Notarangelo LD et al: International Union of Immunological Societies Expert Committee on Primary Immunodeficiencies: Primary immunodeficiencies: 2009 update. *J Allergy Clin Immunol* 124:1161, 2009
11. Pierson JC et al: Cutaneous and visceral granulomas in common variable immunodeficiency. *Cutis* 52:221, 1993
12. Torrelo A, Mediero IG, Zambrano A: Caseating cutaneous granulomas in a child with common variable immunodeficiency. *Pediatr Dermatol* 12:170, 1995
13. Wang J, Cunningham-Rundles C: Treatment and outcome of autoimmune hematologic disease in common variable immunodeficiency (CVID). *J Autoimmun* 25:57, 2005
14. Cunningham-Rundles C: Clinical and immunologic analyses of 103 patients with common variable immunodeficiency. *J Clin Immunol* 9:22, 1989
15. Cunningham-Rundles C et al: Incidence of cancer in 98 patients with common varied immunodeficiency. *J Clin Immunol* 7:294, 1987
16. Spickett GP: Current perspectives on common variable immunodeficiency (CVID). *Clin Exp Allergy* 31:536, 2001
17. Kokron CM et al: Clinical and laboratory aspects of common variable immunodeficiency. *An Acad Bras Cienc* 76:707, 2004
18. Pourpak Z et al: Effect of regular intravenous immunoglobulin therapy on prevention of pneumonia in patients with common variable immunodeficiency. *J Microbiol Immunol Infect* 39:114, 2006
19. Weiler CR, Bankers-Fulbright JL: Common variable immunodeficiency: Test indications and interpretations. *Mayo Clin Proc* 80:1187, 2005
20. Goldacker S, Warnatz K: Tackling the heterogeneity of CVID. *Curr Opin Allergy Clin Immunol* 5:504, 2005
21. Tsukada S et al: Deficient expression of a B cell cytoplasmic tyrosine kinase in human Xlinked agammaglobulinemia. *Cell* 72:279, 1993
22. Sennhauser FH et al: Anti-IgA antibodies in IgA-deficient children. *J Clin Immunol* 8:356, 1988
23. Ferreira A et al: Anti-IgA antibodies in selective IgA deficiency and in primary immunodeficient patients treated with gamma-globulin. *Clin Immunol Immunopathol* 47:199, 1988
24. Sumegi J et al: Correlation of mutations of the SH2D1A gene and Epstein-Barr virus infection with clinical phenotype and outcome in X-linked lymphoproliferative disease. *Blood* 96:3118, 2000

25. Skare JC et al: Linkage analysis of seven kindreds with the X-linked lymphoproliferative syndrome (XLP) confirms that the XLP locus is near DXS42 and DXS37. *Hum Genet* **82**:354, 1989
26. Nichols KE et al: Molecular and cellular pathogenesis of X-linked lymphoproliferative disease. *Immunol Rev* **203**:180, 2005
27. Bassiri H et al: X-linked lymphoproliferative disease (XLP): A model of impaired anti-viral, anti-tumor and humoral immune responses. *Immunol Res* **42**:145, 2008
28. Seemayer TA et al: X-linked lymphoproliferative disease: Twenty-five years after the discovery. *Pediatr Res* **38**:471, 1995
29. Dutz JP et al: Lymphocytic vasculitis in X-linked lymphoproliferative disease. *Blood* **97**:95, 2001
30. Lilic D et al: Deregulated production of protective cytokines in response to *Candida albicans* infection in patients with chronic mucocutaneous candidiasis. *Infect Immunol* **71**:5690, 2003
31. Puel A et al: Autoantibodies against IL-17A, IL-17F, and IL-22 in patients with chronic mucocutaneous candidiasis and autoimmune polyendocrine syndrome type I. *J Exp Med* **207**:291, 2009
32. Ahonen P et al: Clinical variation of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) in a series of 68 patients. *N Engl J Med* **322**:1829, 1990
33. Kirkpatrick CH: Chronic mucocutaneous candidiasis. *Pediatr Infect Dis J* **20**:197, 2001
34. Liston A et al: Aire regulates negative selection of organ-specific T cells. *Nat Immunol* **4**:350, 2003
35. Notarangelo LD, Gambineri E, Badolato R: Immunodeficiencies with autoimmune consequences. *Adv Immunol* **89**:321, 2006
36. Halabi-Tawil M et al: Cutaneous manifestations of immune dysregulation, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome. *Br J Dermatol* **160**:645, 2009
37. Collins SM et al: Dermatological manifestations of autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy syndrome. *Br J Dermatol* **154**:1088, 2006
38. Tosti A et al: Itraconazole in the treatment of two young brothers with chronic mucocutaneous candidiasis. *Pediatr Dermatol* **14**:146, 1997
39. Chinen J et al: Long-term assessment of T-cell populations in DiGeorge syndrome. *J Allergy Clin Immunol* **111**:573, 2003
40. Hong R: The DiGeorge anomaly (CATCH 22, DiGeorge/velocardiofacial syndrome). *Semin Hematol* **35**:282, 1998
41. Merscher S et al: TBX1 is responsible for cardiovascular defects in velo-cardio-facial/DiGeorge syndrome. *Cell* **104**:619, 2001
42. Sullivan KE: The clinical, immunological, and molecular spectrum of chromosome 22q11.2 deletion syndrome and DiGeorge syndrome. *Curr Opin Allergy Clin Immunol* **4**:505, 2004
43. Bonilla FA, Geha RS: Update on primary immunodeficiency diseases. *J Allergy Clin Immunol* **117**:S435, 2006
44. Markert ML et al: Postnatal thymus transplantation with immunosuppression as treatment for DiGeorge syndrome. *Blood* **104**:2574, 2004
45. de la Chapelle A et al: A deletion in chromosome 22 can cause DiGeorge syndrome. *Hum Genet* **57**:253, 1981
46. Driscoll DA et al: Prevalence of 22q11 microdeletions in DiGeorge and velocardiofacial syndromes: Implications for genetic counselling and prenatal diagnosis. *J Med Genet* **30**:813, 1993
47. Markert ML et al: Severe laryngomalacia and bronchomalacia in DiGeorge syndrome and CHARGE association. *Pediatr Pulmonol* **24**:364, 1997
48. Metlay LA, Smythe PS, Miller ME: Familial CHARGE syndrome: Clinical report with autopsy findings. *Am J Med Genet* **26**:577, 1987
49. Wang R, Martinez-Frias ML, Graham JM Jr: Infants of diabetic mothers are at increased risk for the oculo-auriculo-vertebral sequence: A case-based and case-control approach. *J Pediatr* **141**:611, 2002
50. McDonald-McGinn DM et al: Malignancy in chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). *Am J Med Genet A* **140**:906, 2006
51. Markert ML et al: Complete DiGeorge syndrome: Persistence of profound immunodeficiency. *J Pediatr* **132**:15, 1998
52. Rice HE et al: Thymic transplantation for complete DiGeorge syndrome: Medical and surgical considerations. *J Pediatr Surg* **39**:1607, 2004
53. Markert ML et al: Thymus transplantation in complete DiGeorge syndrome: Immunologic and safety evaluations in 12 patients. *Blood* **102**:1121, 2003
54. Brennan TE, Pearson RW: Abnormal elastic tissue in cartilage-hair hypoplasia. *Arch Dermatol* **124**:1411, 1988
55. Makitie O, Kaitila I, Savilahti E: Deficiency of humoral immunity in cartilage-hair hypoplasia. *J Pediatr* **137**:487, 2000

56. Ridanpaa M et al: Mutations in the RNA component of RNase MRP cause a pleiotropic human disease, cartilage-hair hypoplasia. *Cell* **104**:195, 2001
57. Sulisalo T et al: Genetic homogeneity of cartilage-hair hypoplasia. *Hum Genet* **95**:157, 1995
58. Hermanns P et al: Consequences of mutations in the non-coding RMRP RNA in cartilagehair hypoplasia. *Hum Mol Genet* **14**:3723, 2005
59. Makitie O et al: Increased incidence of cancer in patients with cartilage-hair hypoplasia. *J Pediatr* **134**:315, 1999
60. Notarangelo LD, Roifman CM, Giliani S: Cartilage-hair hypoplasia: Molecular basis and heterogeneity of the immunological phenotype. *Curr Opin Allergy Clin Immunol* **8**:534, 2008
61. Fuleihan RL: The hyper IgM syndrome. *Curr Allergy Asthma Rep* **1**:445, 2001
62. Winkelstein JA et al: **The X-linked hyper-IgM syndrome: Clinical and immunologic features of 79 patients.** *Medicine (Baltimore)* **82**:373, 2003
63. Notarangelo LD et al: **Defects of class-switch recombination.** *J Allergy Clin Immunol* **117**:855, 2006
64. Ameratunga R et al: Defective antigen-induced lymphocyte proliferation in the X-linked hyper-IgM syndrome. *J Pediatr* **131**:147, 1997
65. Jain A et al: Defects of T-cell effector function and post-thymic maturation in X-linked hyper-IgM syndrome. *J Clin Invest* **103**:1151, 1999
66. Doffinger R et al: X-linked anhidrotic ectodermal dysplasia with immunodeficiency is caused by impaired NF-kappaB signaling. *Nat Genet* **27**:277, 2001
67. Jain A et al: **Specific missense mutations in NEMO result in hyper-IgM syndrome with hypohidrotic ectodermal dysplasia.** *Nat Immunol* **2**:223, 2001
68. Zonana J et al: A novel X-linked disorder of immune deficiency and hypohidrotic ectodermal dysplasia is allelic to incontinentia pigmenti and due to mutations in IKK-gamma (NEMO). *Am J Hum Genet* **67**:1555, 2000
69. de Saint Basile G et al: CD40 ligand expression deficiency in a female carrier of the Xlinked hyper-IgM syndrome as a result of X chromosome lyonization. *Eur J Immunol* **29**:367, 1999
70. Lin SC et al: X-linked hyper-immunoglobulin M syndrome: Molecular genetic study and long-time follow-up of three generations of a Chinese family. *Int Arch Allergy Immunol* **140**:1, 2006
71. Chang MW et al: Mucocutaneous manifestations of the hyper-IgM immunodeficiency syndrome. *J Am Acad Dermatol* **38**:191, 1998
72. Schneider LC: X-linked hyper IgM syndrome. *Clin Rev Allergy Immunol* **19**:205, 2000
73. Jacobsohn DA et al: Nonmyeloablative hematopoietic stem cell transplant for X-linked hyper-immunoglobulin m syndrome with cholangiopathy. *Pediatrics* **113**:e122, 2004
74. Dimicoli S et al: Complete recovery from Cryptosporidium parvum infection with gastroenteritis and sclerosing cholangitis after successful bone marrow transplantation in two brothers with X-linked hyper-IgM syndrome. *Bone Marrow Transplant* **32**:733, 2003
75. Perry GS III et al: The Wiskott-Aldrich syndrome in the United States and Canada (1892-1979). *J Pediatr* **97**:72, 1980
76. Notarangelo LD, Notarangelo LD, Ochs HD: WASP and the phenotypic range associated with deficiency. *Curr Opin Allergy Clin Immunol* **5**:485, 2005
77. Ochs HD, Thrasher AJ: The Wiskott-Aldrich syndrome. *J Allergy Clin Immunol* **117**:725, quiz 739, 2006
78. Bosticardo M et al: Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. *Blood* **113**:6288, 2009
79. Park JY et al: Early deficit of lymphocytes in Wiskott-Aldrich syndrome: Possible role of WASP in human lymphocyte maturation. *Clin Exp Immunol* **136**:104, 2004
80. Orange JS et al: The Wiskott-Aldrich syndrome. *Cell Mol Life Sci* **61**:2361, 2004
81. Schurman SH, Candotti F: Autoimmunity in Wiskott-Aldrich syndrome. *Curr Opin Rheumatol* **15**:446, 2003
82. Sullivan KE et al: A multiinstitutional survey of the Wiskott-Aldrich syndrome. *J Pediatr* **125**:876, 1994
83. Siminovitsh KA: Prenatal diagnosis and genetic analysis of Wiskott-Aldrich syndrome. *Prenat Diagn* **23**:1014, 2003
84. Conley ME et al: An international study examining therapeutic options used in treatment of Wiskott-Aldrich syndrome. *Clin Immunol* **109**:272, 2003
85. Ozsahin H et al: Bone marrow transplantation in 26 patients with Wiskott-Aldrich syndrome from a single center. *J Pediatr* **129**:238, 1996
86. Fischer A: Severe combined immunodeficiencies (SCID). *Clin Exp Immunol* **122**:143, 2000

87. Gaspar HB, Gilmour KC, Jones AM: Severe combined immunodeficiency—Molecular pathogenesis and diagnosis. *Arch Dis Child* **84**:169, 2001
88. Gennery AR, Cant AJ: Diagnosis of severe combined immunodeficiency. *J Clin Pathol* **54**:191, 2001
89. Rudd CE: Disabled receptor signaling and new primary immunodeficiency disorders. *N Engl J Med* **354**:1874, 2006
90. Buckley RH: The multiple causes of human SCID. *J Clin Invest* **114**:1409, 2004
91. Markert ML: Purine nucleoside phosphorylase deficiency. *Immunodef Rev* **3**:45, 1991
92. Kung C et al: Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. *Nat Med* **6**:343, 2000
93. O'Driscoll M et al: DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. *Mol Cell* **8**:175, 2001
94. de la Calle-Martin O et al: Familial CD8 deficiency due to a mutation in the CD8 alpha gene. *J Clin Invest* **108**:117, 2001
95. Elder ME et al: Human severe combined immunodeficiency due to a defect in ZAP-70, a T cell tyrosine kinase. *Science* **264**:1596, 1994
96. Soudais C et al: Independent mutations of the human CD3-epsilon gene resulting in a T cell receptor/CD3 complex immunodeficiency. *Nat Genet* **3**:77, 1993
97. Frank J et al: Exposing the human nude phenotype. *Nature* **398**:473, 1999
98. Denianke KS et al: Cutaneous manifestations of maternal engraftment in patients with severe combined immunodeficiency: A clinicopathologic study. *Bone Marrow Transplant* **28**:227, 2001
99. Kwong PC et al: Oral and genital ulceration: A unique presentation of immunodeficiency in Athabaskan-speaking American Indian children with severe combined immunodeficiency. *Arch Dermatol* **135**:927, 1999
100. Ege M et al: Omenn syndrome due to ARTEMIS mutations. *Blood* **105**:4179, 2005
101. Giliani S et al: Omenn syndrome in an infant with IL7RA gene mutation. *J Pediatr* **148**:272, 2006
102. Worth A, Thrasher AJ, Gaspar HB: Autoimmune lymphoproliferative syndrome: Molecular basis of disease and clinical phenotype. *Br J Haematol* **133**:124, 2006
103. Roifman CM, Gu Y, Cohen A: Mutations in the RNA component of RNase mitochondrial RNA processing might cause Omenn syndrome. *J Allergy Clin Immunol* **117**:897, 2006
104. Pirovano S et al: Impaired thymic output and restricted T-cell repertoire in two infants with immunodeficiency and early-onset generalized dermatitis. *Immunol Lett* **86**:93, 2003
105. Puck JM, Malech HL: Gene therapy for immune disorders: Good news tempered by bad news. *J Allergy Clin Immunol* **117**:865, 2006
106. Buckley RH et al: Hematopoietic stem-cell transplantation for the treatment of severe combined immunodeficiency. *N Engl J Med* **340**:508, 1999
107. Aiuti A et al: Gene therapy for immunodeficiency due to adenosine deaminase deficiency. *N Engl J Med* **360**:447, 2009
108. Orange JS et al: The presentation and natural history of immunodeficiency caused by nuclear factor kappaB essential modulator mutation. *J Allergy Clin Immunol* **113**:725, 2004
109. Courtois G et al: A hypermorphic IkappaBalpha mutation is associated with autosomal dominant anhidrotic ectodermal dysplasia and T cell immunodeficiency. *J Clin Invest* **112**:1108, 2003
110. Baeuerle PA, Baltimore D: Activation of DNA-binding activity in an apparently cytoplasmic precursor of the NF-kappa B transcription factor. *Cell* **53**:211, 1988
111. Israel A: The IKK complex: An integrator of all signals that activate NF-kappaB? *Trends Cell Biol* **10**:129, 2000
112. Rothwarf DM et al: IKK-gamma is an essential regulatory subunit of the IkappaB kinase complex. *Nature* **395**:297, 1998
113. Martinez-Pomar N et al: A new mutation in exon 7 of NEMO gene: Late skewed X-chromosome inactivation in an incontinentia pigmenti female patient with immunodeficiency. *Hum Genet* **118**:458, 2005
114. Orange JS, Geha RS: Finding NEMO: Genetic disorders of NF-[kappa]B activation. *J Clin Invest* **112**:983, 2003
115. Uzel G: The range of defects associated with nuclear factor kappaB essential modulator. *Curr Opin Allergy Clin Immunol* **5**:513, 2005
116. Orange JS et al: Human nuclear factor kappa B essential modulator mutation can result in immunodeficiency without ectodermal dysplasia. *J Allergy Clin Immunol* **114**:650, 2004

117. Orange JS, Levy O, Geha RS: Human disease resulting from gene mutations that interfere with appropriate nuclear factor-kappaB activation. *Immunol Rev* **203**:21, 2005
118. Puel A et al: Inherited disorders of NF-kappaB-mediated immunity in man. *Curr Opin Immunol* **16**:34, 2004
119. Niehues T et al: Nuclear factor kappaB essential modulator-deficient child with immunodeficiency yet without anhidrotic ectodermal dysplasia. *J Allergy Clin Immunol* **114**:1456, 2004
120. Hanson EP et al: Hypomorphic NEMO mutation database and reconstitution system identifies phenotypic and immunologic diversity. *J Allergy Clin Immunol* **122**:1169, 2008
121. Dupuis-Girod S et al: Successful allogeneic hemopoietic stem cell transplantation in a child who had anhidrotic ectodermal dysplasia with immunodeficiency. *Pediatrics* **118**:e205, 2006
122. Scott SP et al: Missense mutations but not allelic variants alter the function of ATM by dominant interference in patients with breast cancer. *Proc Natl Acad Sci USA* **99**:925, 2002
123. Swift M et al: Incidence of cancer in 161 families affected by ataxia-telangiectasia. *N Engl J Med* **325**:1831, 1991
124. Lavin MF: Ataxia-telangiectasia: from a rare disorder to a paradigm for cell signalling and cancer. *Nat Rev Mol Cell Biol* **9**:759, 2008
125. Lee JH, Paull TT: ATM activation by DNA double-strand breaks through the Mre11- Rad50-Nbs1 complex. *Science* **308**:551, 2005
126. Lim DS et al: ATM phosphorylates p95/nbs1 in an S-phase checkpoint pathway. *Nature* **404**:613, 2000
127. Hannan MA et al: Deficiency in the repair of UV-induced DNA damage in human skin fibroblasts compromised for the ATM gene. *Carcinogenesis* **23**:1617, 2002
128. Cohen LE et al: Common and uncommon cutaneous findings in patients with ataxia-telangiectasia. *J Am Acad Dermatol* **10**:431, 1984
129. Paller AS et al: Cutaneous granulomatous lesions in patients with ataxia-telangiectasia. *J Pediatr* **119**:917, 1991
130. Morrell D, Cromartie E, Swift M: Mortality and cancer incidence in 263 patients with ataxia-telangiectasia. *J Natl Cancer Inst* **77**:89, 1986
131. Loeb DM, Lederman HM, Winkelstein JA: Lymphoid malignancy as a presenting sign of ataxia-telangiectasia. *J Pediatr Hematol Oncol* **22**:464, 2000
132. Nowak-Wegrzyn A et al: Immunodeficiency and infections in ataxia-telangiectasia. *J Pediatr* **144**:505, 2004
133. Lai CH et al: Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. *Proc Natl Acad Sci USA* **101**:15676, 2004
134. Dinauer MC: Disorders of neutrophil function: an overview. *Methods Mol Biol* **412**:489, 2007
135. Winkelstein JA et al: Chronic granulomatous disease. Report on a national registry of 368 patients. *Medicine (Baltimore)* **79**:155, 2000
136. Rosenzweig SD, Holland SM: Phagocyte immunodeficiencies and their infections. *J Allergy Clin Immunol* **113**:620, 2004
137. Reeves EP et al: Killing activity of neutrophils is mediated through activation of proteases by K+ flux. *Nature* **416**:291, 2002
138. Fang FC: Antimicrobial reactive oxygen and nitrogen species: Concepts and controversies. *Nat Rev Microbiol* **2**:820, 2004
139. Foti C et al: Lupus erythematosus-like lesions in a carrier of X-linked chronic granulomatous disease: A case report and personal considerations. *Int J Dermatol* **43**:840, 2004
140. O'Gorman MR, Corrochano V: Rapid whole-blood flow cytometry assay for diagnosis of chronic granulomatous disease. *Clin Diag Lab Immunol* **2**:227, 1995
141. Gallin JI et al: Itraconazole to prevent fungal infections in chronic granulomatous disease. *N Engl J Med* **348**:2416, 2003
142. The International Chronic: A controlled trial of interferon gamma to prevent infection in chronic granulomatous disease. The International Chronic Granulomatous Disease Cooperative Study Group. *N Engl J Med* **324**:509, 1991
143. Dinauer MC: Chronic granulomatous disease and other disorders of phagocyte function. *Hematology Am Soc Hematol Educ Program* 89-95, 2005
144. Soncini E et al: Unrelated donor and HLA-identical sibling haematopoietic stem cell transplantation cure chronic granulomatous disease with good long-term outcome and growth. *Br J Haematol* **145**:73, 2009
145. Etzioni A: Genetic etiologies of leukocyte adhesion defects. *Curr Opin Immunol* **21**:481, 2009
146. Qasim W et al: Allogenic hematopoietic stem cell transplantation for leukocyte adhesion deficiency. *Pediatrics* **123**:836, 2009

147. Bauer TR et al: Retroviral-mediated gene transfer of the leukocyte integrin CD18 into peripheral blood CD34+ cells derived from a patient with leukocyte adhesion deficiency type 1. *Blood* **91**:1520, 1998
148. Gribmacher B, Holland SM, Puck JM: Hyper-IgE syndromes. *Immunol Rev* **203**:244, 2005
149. Minegishi Y et al: Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome. *Nature* **448**:1058, 2007
150. Steven M et al: STAT3 mutations in the hyper-IgE syndrome. *N Engl J Med* **357**:1608, 2007
151. Renner ED et al: Novel signal transducer and activator of transcription 3 (STAT3) mutations, reduced TH17 cell numbers, and variably defective STAT3 phosphorylation in hyper-IgE syndrome. *J Allergy Clin Immunol* **122**:181, 2008
152. Minegishi Y et al: Human tyrosine kinase 2 deficiency reveals its requisite roles in multiple cytokine signals involved in innate and acquired immunity. *Immunity* **25**:745, 2006
153. Zhang Q et al: Combined immunodeficiency associated with DOCK8 mutations. *N Engl J Med* **361**:2046, 2009
154. Engelhardt KR et al: Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal-recessive form of hyper-IgE syndrome. *J Allergy Clin Immunol* **124**:1289, 2009
155. Chamlin SL et al: Cutaneous manifestations of hyper-IgE syndrome in infants and children. *J Pediatr* **141**:572, 2002
156. Eberting CL et al: Dermatitis and the newborn rash of hyper-IgE syndrome. *Arch Dermatol* **140**:1119, 2004
157. Renner ED et al: Autosomal recessive hyperimmunoglobulin E syndrome: A distinct disease entity. *J Pediatr* **144**:93, 2004
158. Etzioni A et al: Cyclosporin A in hyperimmunoglobulin E syndrome. *Ann Allergy Asthma Immunol* **78**:413, 1997
159. Hernandez PA et al: Mutations in the chemokine receptor gene CXCR4 are associated with WHIM syndrome, a combined immunodeficiency disease. *Nat Genet* **34**:70, 2003
160. Wolach B et al: Cyclosporin treatment of hyperimmunoglobulin E syndrome. *Lancet* **347**:67, 1996
161. Huizing M et al: Disorders of lysosome-related organelle biogenesis: Clinical and molecular genetics. *Annu Rev Genomics Hum Genet* **9**:359, 2008
162. Stinchcombe J, Bossi G, Griffiths GM: Linking albinism and immunity: The secrets of secretory lysosomes. *Science* **305**:55, 2004
163. Stinchcombe JC, Page LJ, Griffiths GM: Secretory lysosome biogenesis in cytotoxic T lymphocytes from normal and Chediak-Higashi syndrome patients. *Traffic* **1**:435, 2000
164. Barrat FJ et al: Defective CTLA-4 cycling pathway in Chediak-Higashi syndrome: A possible mechanism for deregulation of T lymphocyte activation. *Proc Natl Acad Sci U S A* **96**:8645, 1999
165. Al-Khenaizan S: Hyperpigmentation in Chediak-Higashi syndrome. *J Am Acad Dermatol* **49**:S244, 2003
166. Ishii E et al: Genetic subtypes of familial hemophagocytic lymphohistiocytosis: Correlations with clinical features and cytotoxic T lymphocyte/natural killer cell functions. *Blood* **105**:3442, 2005
167. Straus SE et al: The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. *Blood* **98**:194, 2001
168. Sharfe N et al: Human immune disorder arising from mutation of the alpha chain of the interleukin-2 receptor. *Proc Natl Acad Sci U S A* **94**:3168, 1997
169. Carnide EM et al: Chediak-Higashi syndrome: Presentation of seven cases. *Sao Paulo Med J* **116**:1873, 1998
170. Katz P, Zaytoun AM, Fauci AS: Deficiency of active natural killer cells in the Chediak-Higashi syndrome. Localization of the defect using a single cell cytotoxicity assay. *J Clin Invest* **69**:1231, 1982
171. Menasche G et al: Griscelli syndrome restricted to hypopigmentation results from a melanophilin defect (GS3) or a MYO5A F-exon deletion (GS1). *J Clin Invest* **112**:450, 2003
172. Kuroda TS, Itoh T, Fukuda M: Functional analysis of slac2-a/melanophilin as a linker protein between Rab27A and myosin Va in melanosome transport. *Methods Enzymol* **403**:419, 2005
173. Kumar M et al: Griscelli syndrome: Rare neonatal syndrome of recurrent hemophagocytosis. *J Pediatr Hematol Oncol* **23**:464, 2001
174. Sanal O et al: Griscelli disease: Genotype-phenotype correlation in an array of clinical heterogeneity. *J Clin Immunol* **22**:237, 2002
175. Durandy A et al: Prenatal diagnosis of syndromes associating albinism and immune deficiencies (Chediak-Higashi syndrome and variant). *Prenat Diagn* **13**:13, 1993

176. Sjöholm AG et al: Complement deficiency and disease: An update. *Mol Immunol* 43:78, 2006
177. Wen L, Atkinson JP, Giclas PC: Clinical and laboratory evaluation of complement deficiency. *J Allergy Clin Immunol* 113:585, quiz 594, 2004
178. Araujo MN et al: C2 deficiency in blood donors and lupus patients: Prevalence, clinical characteristics and HLA-associations in the Brazilian population. *Lupus* 6:462, 1997
179. Johnson CA et al: Molecular heterogeneity of C2 deficiency. *N Engl J Med* 326:871, 1992
180. Casanova JL, Abel L: Human mannose-binding lectin in immunity: Friend, foe, or both? *J Exp Med* 199:1295, 2004
181. Sontheimer RD, Racila E, Racila DM: C1q: Its functions within the innate and adaptive immune responses and its role in lupus autoimmunity. *J Invest Dermatol* 125:14, 2005
182. Botto M: C1q knock-out mice for the study of complement deficiency in autoimmune disease. *Exp Clin Immunogenet* 15:231, 1998
183. Pickering MC et al: Ultraviolet-radiation-induced keratinocyte apoptosis in C1q-deficient mice. *J Invest Dermatol* 117:52, 2001
184. Carroll MC: A protective role for innate immunity in systemic lupus erythematosus. *Nat Rev Immunol* 4:825, 2004
185. Litzman J et al: Early manifestation and recognition of C2 complement deficiency in the form of pyogenic infection in infancy. *J Paediatr Child Health* 39:274, 2003
186. Sjöholm AG: Inherited complement deficiency states: Implications for immunity and immunological disease. *Apmis* 98:861, 1990
187. Peces R: [Partial lipodystrophy in two HLA identical sisters with hypocomplementemia and nephropathy]. [Article in Spanish.] *Nefrologia* 22:564, 2002
188. Noris M et al: Familial haemolytic uraemic syndrome and an MCP mutation. *Lancet* 362:1542, 2003
189. Platonov AE et al: Long term effects of vaccination of patients deficient in a late complement component with a tetravalent meningococcal polysaccharide vaccine. *Vaccine* 21:4437, 2003
190. Tosi M: Molecular genetics of C1 inhibitor. *Immunobiology* 199:358, 1998
191. Jiang H et al: Recombinant adenovirus vectors activate the alternative complement pathway, leading to the binding of human complement protein C3 independent of anti-ad antibodies. *Mol Ther* 10:1140, 2004
192. Bork K et al: Hereditary angioedema with normal C1-inhibitor activity in women. *Lancet* 356:213, 2000
193. Bork K, Gul D, Dewald G: Hereditary angioedema with normal C1 inhibitor in a family with affected women and men. *Br J Dermatol* 154:542, 2006
194. Verpy E et al: Exhaustive mutation scanning by fluorescence-assisted mismatch analysis discloses new genotype-phenotype correlations in angioedema. *Am J Hum Genet* 59:308, 1996
195. Laffort C et al: Severe cutaneous papillomavirus disease after haemopoietic stem-cell transplantation in patients with severe combined immune deficiency caused by common gamma cytokine receptor subunit or JAK-3 deficiency. *Lancet* 363:2051, 2004

